MCL and miR-18b

Analysis of diagnostic mantle cell lymphoma (MCL) samples from the Nordic MCL2 (n= 74) and Nordic MCL3 (n = 94) clinical trials showed that overexpression of miR-18b identified patients with a poor prognosis.

All patients had been treated with rituximab plus chemotherapy as well as autologous stem cell transplantation. Compared with miR-92a and miR-378d, miR-18b was superior in predicting high risk. Based on these findings a new MIPI-B-miR prognosticator was created improving identification of high-risk patients compared with MIPI-B (MCL International prognostic index combined biologic index) with respect to cause-specific survival (p = 0.015), overall survival (p = 0.006) and progression-free survival (p <0.001). Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.